Limnopharma is awarded with a Research Project funded by the NEOTEC program (CDTI; Spanish Ministry of Science and Innovation), for new Business Projects from innovative Start-up companies.

The project granted includes a series of experiments for the preclinical development of Limnopharma’s first drug, targeting Retinosis Pigmantaria (RP), as well as experiments to evaluate the potential of Limnopharma drugs to target other ocular pathologies, both human and veterinary.

The project, that will be carried out during the next two years, is budgeted in €354,896, with 70% (€250,000) funded by CDTI. Obtaining this funding means an important milestone for Limnopharma, and highlights both the robustness of our project and the social and economic impact that our drugs might have.